Buy & Sell abrdn Income Credit Strategies Fund (ACP) – abrdn Income Credit Strategies Fund Price Today
Aura AI Summary
Key Stats
- $653.70MMarket Cap
- FinancialsSector
- -6.88%3M Drawdown
- -Enterprise Value
- 17.85%Dividend Yield
- 97 daysTypical Hold Time
abrdn Income Credit Strategies Fund (ACP) is currently valued at a market capitalization of $653.70M. Over the past 52 weeks, abrdn Income Credit Strategies Fund has traded between a low of $5.01 and a high of $5.98, highlighting its annual price range. Over the past three months, abrdn Income Credit Strategies Fund has recorded a drawdown of -6.88%, reflecting recent price volatility. abrdn Income Credit Strategies Fund offers a dividend yield of 17.85%, with the most recent dividend of $0.08 paid on 21 May 26. On average, investors hold abrdn Income Credit Strategies Fund for approximately 97 days, indicating typical investor behavior on the platform.
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Most Recent News
OpenAI plans major upgrade to boost ChatGPT amid IPO and competition with Anthropic.
OpenAI is preparing its biggest upgrade yet, transforming ChatGPT into a superapp with multiple tools like coding and AI agents to better compete with Anthropic. This move aims to attract more corporate clients and increase revenue as OpenAI readies ...

Repatha cuts first major cardiovascular event risk by 29% in high-risk diabetes patients, new trial data show
New Phase 3 VESALIUS-CV trial data reveal that Repatha (evolocumab), added to statins, reduces the risk of first major cardiovascular events by 29% in patients with high-risk diabetes and elevated LDL cholesterol. The study involved 6,002 patients wi...

Investors may claim losses after ADMA Biologics shares fell 16.6% amid fraud allegations.
Rosen Law Firm is investigating securities claims against ADMA Biologics following allegations that the company misled investors by inflating revenue through channel stuffing. The stock dropped 16.6% on March 24, 2026, after a short seller report by ...
